"I love Lookatmet"

2022-10-07 15:28:12

Over 50% of patients with NSCLC may have an oncogenic alteration1,2 The identification of new targetable alterations could potentially change the approach to NSCLC treatment. Find out more about targetable oncogenic drivers for patients with NSCLC 1,2" style="background-color: #FFFFFF; color: #2DBECD !important;" href="/en/home/oncogenic-drivers.html" target="_self"> Find out about oncogenic drivers ~6% of patients with NSCLC may have a MET-alteredtumor3,4 With its role in driving NSCLC, MET is a biomarker that should be carefully considered5Find out more about what MET alterations could mean for patients with NSCLC MET-alteredtumor3,4" style="background-color: #FFFFFF; color: #2DBECD !important;" href="/en/home/met-alterations.html" target="_self"> Find out about MET alterations Diagnostic panels should include METex14 skipping from the start METex14 skipping can be detected using tissue or liquid biopsyFind out more about the biopsy options available for these patients METex14 skipping from the start" style="background-color: #FFFFFF; color: #2DBECD !important;" href="/en/home/testing.html" target="_self"> Find out about biopsy options References and Abbreviations: Expand all Collapse all 1. Pakkala S, Ramalingam SS. JCI Insight 2018; 3:e120858.2. Grosse A et al. Diagn Pathol 2019; 14:18.3. Salgia R. Mol Cancer Ther 2017; 16:555–565.4. Ikeda S et al. J Hematol Oncol 2018: 11:76.5. Tong JH et al. Clin Cancer Res 2016; 22:3048–3056. Cookie Disclaimer By browsing, you agree to the use of cookies to analyse how you use our website and help us to make improvements accordingly. Learn more OK Are you a healthcare professional? The purpose of this website is to educate and inform healthcare professionals about NSCLC YES      Continue NO Not a healthcare professional? Visit our public site Continue .back-to-top__btn { background-color: #2DBECD; }